Infant Vaccination(유아 예방 접종)란 무엇입니까?
Infant Vaccination 유아 예방 접종 - Diphtheria-tetanus-pertussis (DTP) combination vaccines are a cornerstone of infant vaccinations worldwide. [1] Two PCVs are widely available for infant vaccination: the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and the 13-valent PCV (PCV13). [2] This study used a dynamic transmission model to compare two base-case varicella vaccination schedules (no infant vaccination or 10% coverage with infant vaccination) versus three universal varicella vaccination (UVV) schedules using a MMR-varicella zoster vaccine (ProQuad; MMRV-MSD) or a standalone varicella vaccine (Varivax; V-MSD), with a 3, 7, or 12-month interval between the first and second dose. [3] Infant vaccination was associated with higher CE ratios in low- and high-income settings. [4] Shifting serotype distribution due to the indirect effect of infant vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) may continue to increase the gap between 23-valent pneumococcal polysaccharide vaccine (PPSV23) and PCV13 serotype coverage for older adults in the coming years. [5] In all three states, maternal aP vaccination was estimated to save more lives of infants and increase disabilityadjusted life years (DALYs) averted compared with infant vaccination only, but was associated with higher costs, resulting in estimated incremental cost-effectiveness ratios (ICERs) of $2022 per DALY averted in Bahia, $2962 per DALY averted in Parana, and $3068 per DALY averted in Sao Paulo. [6] Background Growing evidence shows that many parents begin the decision-making process about infant vaccination during pregnancy and these decisions – once established – may be resistant to change. [7] Objectives Using dynamic transmission models we evaluated the health and cost outcomes of adding acellular pertussis (aP) vaccination of pregnant women to infant vaccination in three Brazilian states that represent different socioeconomic conditions. [8] [1] In this article, the authors aimed to evaluate the effect of timing of infant vaccination with Bacillus Calmette Gu erin (BCG), DTP1, and measles vaccine (MV) on stunting, among other outcomes. [9] A paper prominently circulated on social media concluded that countries requiring more infant vaccinations have higher infant mortality rates (IMR), which has serious public health implications. [10] Methods: A dynamic transmission model for varicella was adapted to Switzerland comparing 2 base-case schedules (no infant vaccination and 10% coverage with infant vaccination) to 3 different UVV schedules using quadrivalent (varicella vaccine combined with measles-mumps-rubella) and standalone varicella vaccines administered at different ages. [11] Four Acceptance articles report on willingness to accept and pay for a dengue vaccine in Bangladesh (Kabir, p 773), vaccine knowledge and attitudes of Muslim parents in Malaysia (Ansari, p 785), predictors of vaccine uptake among HIV patients in a specialty care clinic (Johnson, p 791), and caregivers’ satisfaction with infant vaccination in Ethiopia (Dana, p 797). [12] Various suggestions put forward to account for this included the possibility that LMICs might be experiencing off-target benefits of infant vaccination with BCG, intended primarily to protect against tuberculosis. [13] However, little has been documented about their recommendations for, and administration of, prenatal and infant vaccinations. [14] Conclusions: This study provides evidence of a lack of vaccination catch-up after the first lockdown and a persistent shortfall in infant vaccination after the first 10 months of the COVID-19 pandemic in France, especially for the MMR priming doses and Men-C-C booster. [15] 90 for MenC <1 year after infant vaccination, indicating higher antibody levels in girls. [16] This study investigated the effect of maternal parasitic infections on infant vaccination in a more recent setting of active anti-parasitic therapy. [17] BackgroundPassive transferred antibodies to the fetus play an essential role on protecting neonates and young infants until infant vaccination is more efficacious. [18] Despite its efficacy to prevent HBV transmission, infant vaccination is not enough to control HBV MTCT. [19] The Hepatitis B section presents a systematic review of suitable vaccines for adult immunization in China (Wu, p 221), a report on infant vaccination in rural China among the 1997-2011 birth cohorts (Wangen, p 229), and antibody persistence analysis in adolescents vaccinated in infancy with four doses of the hexavalent combination vaccine (Schwarz, p 236). [20] Studies have shown that for several vaccines, such as live attenuated, toxoid and conjugated vaccines, high maternal antibody titers inhibit the infant's humoral immune response after infant vaccination. [21] 5, 9, and 27 months); infant vaccination (doses at ages 6, 10, and 14 weeks and 21 months); no malaria vaccination. [22] Professional guidance is required for patient education, optimizing treatment before pregnancy, disease management during pregnancy, choosing delivery mode, disease management during lactation, and infant vaccination. [23] Scaling up of infant vaccination has already demonstrated an impact on global HBV prevalence26. [24] A global BCG vaccine shortage began in 2013 which impacted availability for infant vaccinations, as well as preclinical studies and clinical trials of new TB vaccines. [25] Resources including information relating to infant vaccination and available to Canadians were included. [26] There would be universal antenatal screening for HIV, STIs and hepatitis B (or infant vaccination at birth) with combined efforts to reduce mother to child transmission of HIV, syphilis and hepatitis B. [27] Prior research demonstrates that mothers are the primary decision maker for infant vaccination, and that their vaccination attitudes form primarily during pregnancy and early in their infant’s life. [28] Vaccine refusing/delaying parents were more frequently those who agreed that infant vaccinations are primarily an economic business of pharmaceutical companies, and who disagreed that access to the kindergarten should only be allowed to children who had been vaccinated. [29]nan [1] nan [2] nan [3] nan [4] nan [5] nan [6] nan [7] nan [8] nan [9] nan [10] nan [11] nan [12] nan [13] nan [14] nan [15] MenC의 경우 유아 백신 접종 후 1년 미만인 경우 90으로, 여아에서 더 높은 항체 수준을 나타냅니다. [16] 이 연구는 보다 최근의 능동적인 항기생충 요법에서 유아 예방접종에 대한 산모 기생충 감염의 영향을 조사했습니다. [17] 배경태아에 대한 수동 전달 항체는 유아 예방 접종이 더 효과적일 때까지 신생아와 어린 유아를 보호하는 데 필수적인 역할을 합니다. [18] HBV 전파를 예방하는 효능에도 불구하고 유아 백신 접종은 HBV MTCT를 제어하기에 충분하지 않습니다. [19] B형 간염 섹션에서는 중국의 성인 예방접종에 적합한 백신에 대한 체계적인 검토(Wu, p 221), 1997-2011년 출생 코호트(Wangen, p 229) 중 중국 농촌 지역의 유아 예방 접종에 대한 보고서 및 항체 지속성 분석을 제공합니다. 영아기에 6가 혼합 백신을 4회 접종한 청소년(Schwarz, p 236). [20] 연구에 따르면 약독화 생백신, 톡소이드 및 접합 백신과 같은 여러 백신의 경우 높은 모체 항체 역가가 유아 백신 접종 후 유아의 체액성 면역 반응을 억제하는 것으로 나타났습니다. [21] 5, 9, 27개월); 유아 예방 접종(6, 10, 14주 및 21개월에 접종); 말라리아 예방 접종이 없습니다. [22] 환자 교육, 임신 전 최적의 치료, 임신 중 질병 관리, 분만 방식 선택, 수유 중 질병 관리, 유아 예방 접종을 위해서는 전문적인 지도가 필요합니다. [23] 유아 예방 접종의 확대는 이미 전 세계 HBV 유병률에 영향을 미치는 것으로 나타났습니다26. [24] 2013년 전 세계적으로 BCG 백신 부족이 시작되어 유아 예방 접종의 가용성과 새로운 TB 백신의 전임상 연구 및 임상 시험에 영향을 미쳤습니다. [25] 유아 예방 접종에 관한 정보와 캐나다인이 이용할 수 있는 정보를 포함한 리소스가 포함되었습니다. [26] HIV, STI 및 B형 간염(또는 출생 시 유아 예방 접종)에 대한 보편적인 산전 선별 검사와 HIV, 매독 및 B형 간염의 엄마에서 아이로의 전염을 줄이기 위한 공동 노력이 있을 것입니다. [27] 이전 연구에 따르면 어머니는 유아 예방 접종의 주요 결정자이며 어머니의 예방 접종 태도는 주로 임신 기간과 유아의 초기 단계에 형성됩니다. [28] 예방접종을 거부/미루는 부모는 유아 예방접종이 주로 제약회사의 경제적 사업이라는 데 동의하고, 예방접종을 받은 어린이에게만 유치원 출입을 허용해야 한다는 데 동의하지 않는 부모가 더 많았습니다. [29]
valent pneumococcal conjugate
BACKGROUND Few studies have measured the burden of adult pneumococcal disease after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into the US infant vaccination schedule. [1] INTRODUCTION Implementation of the 7-valent pneumococcal conjugate vaccine (PCV7) in infant vaccination programs has substantially reduced the burden of PCV7 serotypes also in adult community-acquired pneumonia (CAP). [2] BACKGROUND The 13-valent pneumococcal conjugate vaccine (PCV13) is used for universal infant vaccination in Turkey. [3]배경 미국 유아 예방접종 일정에 13가 폐렴구균 결합백신(PCV13)이 도입된 후 성인 폐렴구균 질환의 부담을 측정한 연구는 거의 없습니다. [1] 소개 유아 예방 접종 프로그램에서 7가 폐렴 구균 접합 백신(PCV7)의 구현은 성인 지역사회 획득 폐렴(CAP)에서도 PCV7 혈청형의 부담을 상당히 줄였습니다. [2] nan [3]
pneumococcal conjugate vaccine
Pneumococcal conjugate vaccines (PCVs) were introduced into the US routine infant vaccination schedule leading to substantial reductions of invasive pneumococcal diseases (IPD). [1] Widespread infant vaccination with pneumococcal conjugate vaccines (PCVs) substantially reduced vaccine-serotype pneumococcal disease by direct protection of immunized children and indirect protection of the community via decreased nasopharyngeal carriage and transmission. [2]폐렴구균 접합 백신(PCV)이 미국의 정기 유아 예방 접종 일정에 도입되어 침습성 폐렴구균 질환(IPD)이 크게 감소했습니다. [1] 폐렴구균 결합백신(PCV)을 사용한 광범위한 유아 예방접종은 예방접종을 받은 어린이를 직접 보호하고 비인두 운반 및 전파 감소를 통해 지역사회를 간접적으로 보호함으로써 백신-혈청형 폐렴구균 질병을 실질적으로 감소시켰습니다. [2]
Routine Infant Vaccination 정기 유아 예방 접종
Routine infant vaccination was considered the most effective short-term strategy, whereas combined infant and adolescent vaccination provided maximal long-term health benefits. [1] • The background effect of routine infant vaccination is critical to the cost-effectiveness of maternal aP immunization. [2] Reported trends in CRS incidence showed elimination within five years of RCV introduction with scenarios involving mass vaccination of older children in addition to routine infant vaccination. [3] We aimed to assess the impact of the COVID-19 pandemic on the incidence of vaccine-preventable diseases (VPDs) and participation in the routine infant vaccination programme in the Netherlands. [4] Routine infant vaccination was the most effective short-term strategy, however, adolescent strategies offered the best value for money. [5] Pneumococcal conjugate vaccines (PCVs) were introduced into the US routine infant vaccination schedule leading to substantial reductions of invasive pneumococcal diseases (IPD). [6] Polyvalent meningococcal conjugate (PMC) vaccines may offer alternatives to current strategies that rely on routine infant vaccination with MenAfriVac plus, in the event of an epidemic, district-specific reactive campaigns using polyvalent meningococcal polysaccharide (PMP) vaccines. [7] MethodsWe developed a decision-analytic model simulating 10,000 singleton pregnancies to assess the cost-effectiveness of three possible strategies for deployment of tenofovir in pregnancy, in combination with routine infant vaccination: S1: no screening nor antiviral therapy; S2: screening and antiviral prophylaxis for all women who test HBsAg-positive; S3: screening for HBsAg, followed by HBeAg testing and antiviral prophylaxis for women who are HBsAg-positive and HBeAg-positive. [8] Our model predicted use in routine infant vaccination as well as campaigns targeting varying proportions of the unvaccinated population up to 15 years of age. [9] Thus, routine infant vaccination may have resulted to an overall decline of pneumococcal pneumonia in infants, as well as in elderly age groups. [10]nan [1] nan [2] nan [3] nan [4] nan [5] 폐렴구균 접합 백신(PCV)이 미국의 정기 유아 예방 접종 일정에 도입되어 침습성 폐렴구균 질환(IPD)이 크게 감소했습니다. [6] 다가 수막구균 접합체(PMC) 백신은 MenAfriVac 플러스를 통한 일상적인 유아 예방 접종에 의존하는 현재 전략에 대한 대안을 제공할 수 있습니다. [7] nan [8] nan [9] nan [10]
Universal Infant Vaccination 보편적인 유아 예방 접종
BACKGROUND Risk-group HBV vaccination for men who have sex with men (MSM) was introduced in the Netherlands in 2002, followed by universal infant vaccination in 2011, that will enable termination of risk-group vaccination over time. [1] The analysis starts from the current universal infant vaccination of pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV), 2 primary and 1 booster dose at 2, 4, and 12 months, respectively. [2] BACKGROUND The 13-valent pneumococcal conjugate vaccine (PCV13) is used for universal infant vaccination in Turkey. [3]Delayed Infant Vaccination
However, studies comprehensively examining predictors of delayed infant vaccination are lacking. [1] Children born prematurely, small for gestational age, between July and December, with chronic conditions, older siblings, mothers < 30 years old or delayed infant vaccination had a significantly increased risk of admission. [2]그러나 영유아 예방접종 지연의 예측인자를 종합적으로 조사한 연구는 부족한 실정이다. [1] 7월에서 12월 사이에 조산하고, 재태 연령에 비해 작으며, 만성 질환이 있는 어린이, 나이가 많은 형제 자매, 30세 미만의 어머니 또는 유아 예방 접종이 지연된 어린이는 입원 위험이 유의하게 증가했습니다. [2]
Increase Infant Vaccination
CONCLUSION Automated Reminders and with links to heath system resources was not shown to increase infant vaccination uptake demonstrating additional resources are needed to address the needs of caregivers experiencing logistical barriers to vaccination. [1] Text message reminders may be an effective tool to increase infant vaccination coverage in low-income settings by reminding parents to vaccinate. [2]nan [1] 문자 메시지 알림은 부모에게 예방 접종을 상기시켜 저소득 환경에서 유아 예방 접종 범위를 늘리는 효과적인 도구가 될 수 있습니다. [2]
infant vaccination schedule
In Ethiopia, rubella is not prioritized disease under surveillance and its vaccine has not been introduced into infant vaccination schedule. [1] Pneumococcal conjugate vaccines (PCVs) were introduced into the US routine infant vaccination schedule leading to substantial reductions of invasive pneumococcal diseases (IPD). [2] BACKGROUND Few studies have measured the burden of adult pneumococcal disease after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into the US infant vaccination schedule. [3] influenzae protein D was used in the Northern Territory infant vaccination schedule for two years from October 2009. [4] Overall, there is no evidence for a difference in strain coverage when 4CMenB is administered according to a 3 + 1 or 2 + 1 infant vaccination schedule. [5]nan [1] 폐렴구균 접합 백신(PCV)이 미국의 정기 유아 예방 접종 일정에 도입되어 침습성 폐렴구균 질환(IPD)이 크게 감소했습니다. [2] 배경 미국 유아 예방접종 일정에 13가 폐렴구균 결합백신(PCV13)이 도입된 후 성인 폐렴구균 질환의 부담을 측정한 연구는 거의 없습니다. [3] nan [4] nan [5]
infant vaccination coverage 유아 예방 접종 보장
• (82) Maternal aP is cost-effective when infant vaccination coverage is moderate or low. [1] We applied logistic regressions to estimate odds ratios (OR) and 95% confidence intervals (CI) for improved water and sanitation, respectively, and reported antenatal care visits, having a skilled attendant at birth, and infant vaccination coverage, stratified by maternal education. [2] 01) for infant vaccination coverage in 2016. [3] Text message reminders may be an effective tool to increase infant vaccination coverage in low-income settings by reminding parents to vaccinate. [4] This study aimed to investigate infant vaccination coverage for birth cohorts from 1997 to 2011 in rural regions and to assess catch-up vaccination potential. [5]nan [1] nan [2] 01) 2016년 영유아 예방접종 대상. [3] 문자 메시지 알림은 부모에게 예방 접종을 상기시켜 저소득 환경에서 유아 예방 접종 범위를 늘리는 효과적인 도구가 될 수 있습니다. [4] nan [5]
infant vaccination program 유아 예방접종 프로그램
Conclusions on effectiveness of V114 or added value over existing infant vaccination programs cannot be drawn. [1] In conclusion, our data show that i) the infant vaccination program of PCV13, which started in Germany 2010 did not result in a relevant and sustained decrease of PCV13 serotypes in pneumonia in adults and ii) that the gap in the coverage between PCV20 and PPV23 was small and did not increase over the entire observation time. [2] INTRODUCTION Implementation of the 7-valent pneumococcal conjugate vaccine (PCV7) in infant vaccination programs has substantially reduced the burden of PCV7 serotypes also in adult community-acquired pneumonia (CAP). [3]nan [1] nan [2] 소개 유아 예방 접종 프로그램에서 7가 폐렴 구균 접합 백신(PCV7)의 구현은 성인 지역사회 획득 폐렴(CAP)에서도 PCV7 혈청형의 부담을 상당히 줄였습니다. [3]
infant vaccination visit
ObjectiveThe Manitoba Infant Feeding Database (MIFD) is being piloted as a surveillance system leveraging infant vaccination visits as a point of contact to collect infant feeding data during the first year of life. [1] The Choosing Healthy Eating for Infant Health (CHErIsH) intervention is a complex infant feeding intervention delivered at infant vaccination visits, alongside a healthcare professional (HCP)-level implementation strategy to support delivery. [2]목적 매니토바 유아 수유 데이터베이스(MIFD)는 생후 첫 해 동안 유아 수유 데이터를 수집하기 위한 접촉 지점으로 유아 예방 접종 방문을 활용하는 감시 시스템으로 시범 운영되고 있습니다. [1] 유아 건강을 위한 건강한 식생활 선택(CHERIsH) 개입은 출산을 지원하기 위한 의료 전문가(HCP) 수준의 시행 전략과 함께 유아 예방 접종 방문 시 제공되는 복잡한 유아 수유 개입입니다. [2]